Trial Profile
Phase 1: A Single-Center, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Neublastin (Primary)
- Indications Sciatica
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Biogen Idec
- 30 May 2014 New trial record